SVEP1: A Sodium Channel and Pentraxin Domain Containing 1 Target for Therapeutic Intervention

Target Name: SVEP1

NCBI ID: G79987

SVEP1

SVEP1: A Sodium Channel and Pentraxin Domain Containing 1 Target for Therapeutic Intervention

Abstract:

SVEP1, a sodium channel and pentraxin domain containing 1, has been identified as a potential drug target and biomarker for various diseases, including hypertension, heart failure, and autoimmune disorders. This protein plays a crucial role in the regulation of sodium and water transport in various tissues, including the heart, kidneys, and endothelium. The SVEP1 gene has been associated with various cardiovascular diseases, and its expression has been found to be elevated in individuals with hypertension and heart failure.

SVEP1 is a member of the voltage-gated sodium channel (VGSA) family, which is a subfamily of the large conductance calcium channels (LCCAs) that are responsible for maintaining the resting membrane potential of the heart and other excitable tissues. SVEP1 is characterized by a long N-terminus that contains a voltage-dependent autoionization (VDA) domain, a critical region for channel activation, and a C-terminus that is involved in the formation of a voltage-safety loop.

SVEP1 is expressed in a variety of tissues and cells, including cardiac muscle, heart failure cells, kidney podocytes, and endothelial cells. It has been shown to play a crucial role in the regulation of sodium and water transport in these tissues, and its expression has been associated with various cardiovascular diseases, including hypertension, heart failure, and autoimmune disorders.

SVEP1 has been shown to be involved in the regulation of sodium and water transport in various tissues and cells. It plays a crucial role in the regulation of the resting membrane potential of the heart and other excitable tissues.

SVEP1 has also been shown to be involved in the regulation of ion channels in various tissues, including cardiac muscle, heart failure cells, and kidney podocytes. It has been shown to play a crucial role in the regulation of the sodium and calcium channels in these tissues, and its expression has been associated with various cardiovascular diseases, including hypertension, heart failure, and autoimmune disorders.

In addition to its role in the regulation of sodium and water transport, SVEP1 has also been shown to be involved in the regulation of inflammation and cellular signaling. It has been shown to play a crucial role in the regulation of the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6, in various tissues and cells.

SVEP1 has also been shown to be involved in the regulation of the migration and survival of various cell types, including cardiac muscle cells, heart failure cells, and cancer cells. It has been shown to play a crucial role in the regulation of the Src/FAK-associated signaling pathway, which is involved in the regulation of cell motility, adhesion, and survival.

In conclusion, SVEP1 is a critical protein that plays a crucial role in the regulation of sodium and water transport in various tissues and cells. Its expression has been associated with various cardiovascular diseases, including hypertension, heart failure, and autoimmune disorders. As a potential drug target and biomarker, SVEP1 is a promising target for the development of new therapies for these diseases.

Keywords: SVEP1, sodium channel, pentraxin domain, autoionization, voltage-safety loop, cardiovascular disease, drug target, biomarker

Protein Name: Sushi, Von Willebrand Factor Type A, EGF And Pentraxin Domain Containing 1

Functions: May play a role in the cell attachment process

The "SVEP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SVEP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets